LivaNova PLC (NASDAQ:LIVN) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 6.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,770,277 shares of the company's stock after purchasing an additional 100,133 shares during the quarter. Vanguard Group Inc. owned 3.29% of LivaNova worth $93,612,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Teachers Retirement System of The State of Kentucky lifted its stake in LivaNova by 93.6% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 18,370 shares of the company's stock valued at $971,000 after acquiring an additional 8,879 shares during the period. Deutsche Bank AG grew its position in LivaNova by 13.5% in the 3rd quarter. Deutsche Bank AG now owns 27,586 shares of the company's stock worth $1,459,000 after purchasing an additional 3,278 shares during the period. Morgan Stanley raised its stake in LivaNova by 2.7% during the 3rd quarter. Morgan Stanley now owns 355,640 shares of the company's stock valued at $18,806,000 after buying an additional 9,252 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of LivaNova by 21.2% during the 3rd quarter. Royal Bank of Canada now owns 160,051 shares of the company's stock valued at $8,463,000 after buying an additional 27,969 shares during the period. Finally, Sei Investments Co. boosted its stake in shares of LivaNova by 24.1% in the 3rd quarter. Sei Investments Co. now owns 135,882 shares of the company's stock worth $7,185,000 after buying an additional 26,353 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded up $0.70 during mid-day trading on Friday, reaching $53.94. 896,784 shares of the company traded hands, compared to its average volume of 613,618. The company's 50 day moving average price is $52.70 and its 200-day moving average price is $50.62. The firm has a market cap of $2.91 billion, a PE ratio of 168.22 and a beta of 0.89. LivaNova PLC has a 52 week low of $42.25 and a 52 week high of $59.86. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.77 by $0.10. The business had revenue of $310.10 million during the quarter, compared to analyst estimates of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company's revenue was up 12.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.81 earnings per share. On average, equities analysts expect that LivaNova PLC will post 3.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Robert W. Baird increased their target price on LivaNova from $56.00 to $62.00 and gave the company a "neutral" rating in a report on Thursday, February 22nd. Mizuho reissued a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a report on Wednesday, March 27th. Barclays boosted their target price on shares of LivaNova from $57.00 to $61.00 and gave the company an "equal weight" rating in a research report on Monday, February 26th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $72.00 price target on shares of LivaNova in a research report on Wednesday, March 20th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $64.40.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.